RxDoctor Payments Data

Gregory Proctor, MD

Nephrology · Aurora, CONPI 1447306063

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,698 of the $6,600 with a category attached, or 71.2%. AstraZeneca accounts for 90.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $5,826 and has fallen 97.0% since, to $173 in 2025.

$6,600in general payments, 2019–2025

Across 51 payments — averaging $129.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Genentech USA, Inc.$88
  • Vifor Pharma, Inc.$86
  • Aurinia Pharma U.S., Inc.$74
  • Boehringer Ingelheim$71
  • Novartis$66
  • plus $245 from 6 others

What the payments were for

  • Consulting fees$4,69871%
  • Travel & lodging$76212%
  • Food & beverage$1,13917%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,600 in reported general payments places this provider in the 85th percentile of 152 nephrology providers in Colorado.

See all nephrology providers in Colorado

Medicare billing

Part B allowed, 2024
$131,001
Medicare patients
234
Services billed
1,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$64,663
FarxigaDapagliflozin Propanediol69$55,867
Calcitriol33$585
Losartan Potassium31$388
Lisinopril69$377
Tamsulosin Hcl29$333
Hydralazine Hcl26$271
Gabapentin18$267
Furosemide48$262
Allopurinol13$251
Potassium Chloride15$242
Amlodipine Besylate32$222
Labetalol Hcl18$192
Hydrochlorothiazide30$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$71$64,66385 claims
AstraZenecaFarxiga$5,969$55,86769 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 152 nephrology providers in Colorado.

Other nephrology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →